XTLB
XTL Biopharmaceuticals
XTLB
XTLB
3 hedge funds and large institutions have $463K invested in XTL Biopharmaceuticals in 2024 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
1
RhumbLine Advisers
Boston,
Massachusetts
|
$22.6K |
Top Sellers
| 1 |
1
Morgan Stanley
New York
|
$37.2K |
| Name | Market Value | Shares |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
NI
1
Noked Israel
Ramat Hasharon,
Israel
| $403K | 198,888 | – | – |
|
|
2
Morgan Stanley
New York
| $37.2K | 18,351 | -8,100 | -31% |
|
|
3
RhumbLine Advisers
Boston,
Massachusetts
| $22.6K | 10,954 | +4,435 | +68% |
|
|
CFGS
4
Concourse Financial Group Securities
Birmingham,
Alabama
| – | – | – | – |
|